Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (23)

2023

  1. Multi-omics in HIV: searching insights to understand immunological non-response in PLHIV

    Frontiers in Immunology

2019

  1. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010–2015

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 9, pp. 580-587

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2017

  1. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice

    AIDS Research and Human Retroviruses, Vol. 33, Núm. 1, pp. 29-32

2016

  1. Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 6, pp. 471-478

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  3. Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death

    Journal of Acquired Immune Deficiency Syndromes, Vol. 73, Núm. 1, pp. 100-108

  4. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

    Medicine (United States), Vol. 95, Núm. 40

  5. Using observational data to emulate a randomized trial of dynamic treatmentswitching strategies: An application to antiretroviral therapy

    International Journal of Epidemiology, Vol. 45, Núm. 6, pp. 2038-2049

2015

  1. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?

    AIDS, Vol. 29, Núm. 17, pp. 2323-2333

  2. Off-label use of maraviroc in HIV-1-infected paediatric patients in clinical practice

    AIDS, Vol. 29, Núm. 16, pp. 2155-2159

  3. Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095

2014

  1. Evaluation of rapid progressors in HIV infection as an extreme phenotype

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 1, pp. 15-21

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1462-1469

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

  2. The future of antiretroviral therapy: Challenges and needs

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 5, pp. 827-835

2009

  1. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection

    Journal of Viral Hepatitis, Vol. 16, Núm. 4, pp. 249-258

2008

  1. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy

    Journal of Antimicrobial Chemotherapy, Vol. 62, Núm. 2, pp. 234-245